Literature DB >> 29160180

Incidental Findings on FDG PET/CT in Head and Neck Cancer.

Christopher J Britt1, Austin M Maas2, Tabassum A Kennedy3, Gregory K Hartig2.   

Abstract

Objective 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG PET/CT) imaging is common in head and neck cancer and often identifies incidental findings that necessitate additional patient evaluations. Our goal was to assess the frequency and nature of these incidental imaging findings on FDG-PET/CT. Study Design Retrospective cohort study. Setting Tertiary medical center. Subjects and Methods All patients with head and neck cancer who had undergone FDG-PET/CT imaging between January 2014 and June 2015 at our institution were evaluated for incidental findings. Results A total of 293 patients met criteria; more than one-third (n = 103) had at least 1 finding unrelated to their head and neck cancer, for a total of 134 incidental findings. Incidental findings within the head and neck (33.5% of all) excluding the thyroid were most common: 35% incidental findings were concerning for malignancy; of these, 25.5% were malignant with further workup. Recommendations were given by the head and neck radiologist on 72 (53.7%) findings: 74.5% of potentially malignant findings and 42.5% of benign findings had recommendations for follow-up. Significantly more patients with findings described as malignant were given recommendations for follow-up ( P = .0004). Conclusion Incidental findings on FDG-PET/CT are present in more than one-third of patients with head and neck cancer. More than one-third of incidental findings were concerning for malignancy. This study illustrates how the incidental findings discovered on FDG PET/CT frequently necessitate additional evaluations unrelated to the index head and neck cancer. The impact of these additional assessments on the cost and quality of health care warrants future evaluation.

Entities:  

Keywords:  CT; PET; PET/CT; findings; head and neck cancer; imaging; incidental

Mesh:

Substances:

Year:  2017        PMID: 29160180     DOI: 10.1177/0194599817742579

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  A preclinical PET detector constructed with a monolithic scintillator ring.

Authors:  Jianfeng Xu; Siwei Xie; Xi Zhang; Weijie Tao; Jingwu Yang; Zhixiang Zhao; Fenghua Weng; Qiu Huang; Fei Yi; Qiyu Peng
Journal:  Phys Med Biol       Date:  2019-08-07       Impact factor: 3.609

2.  Whole-body hybrid positron emission tomography imaging yields clinically relevant information in the staging and restaging of sinonasal tumors.

Authors:  Alexander Maurer; Christian M Meerwein; Michael B Soyka; Hannes Grünig; Stephan Skawran; Urs J Mühlematter; Michael Messerli; Cäcilia E Mader; Lars Husmann; Niels J Rupp; David Holzmann; Martin W Huellner
Journal:  Head Neck       Date:  2021-09-13       Impact factor: 3.821

3.  FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.

Authors:  Marianne Vogsen; Jeanette Dupont Jensen; Ivar Yannick Christensen; Oke Gerke; Anne Marie Bak Jylling; Lisbet Brønsro Larsen; Poul-Erik Braad; Katrine Lydolph Søe; Camilla Bille; Marianne Ewertz; Malene Grubbe Hildebrandt
Journal:  Breast Cancer Res Treat       Date:  2020-09-12       Impact factor: 4.872

Review 4.  The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging.

Authors:  W Tania Rahman; Daniel J Wale; Benjamin L Viglianti; Danyelle M Townsend; Matthew S Manganaro; Milton D Gross; Ka Kit Wong; Domenico Rubello
Journal:  Biomed Pharmacother       Date:  2019-07-01       Impact factor: 6.529

5.  Impact of pretreatment second look 18FDG-PET/CT on stage and treatment changes in head and neck cancer.

Authors:  Olgun Elicin; Bernd Vollnberg; Mohamed Shelan; Elena Riggenbach; Beat Bojaxhiu; Etienne Mathier; Roland Giger; Daniel M Aebersold; Bernd Klaeser
Journal:  Clin Transl Radiat Oncol       Date:  2021-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.